The subcutaneous implantable cardioverter defibrillator (S-ICD) has been considered as a comparable alternative to transvenous ICD in a wide array of patients (pts) without pacing indication. Recent data have reported high rates of inappropriate (inap) therapies with S-ICD, mostly due to T wave or noise oversensing.
Our aim was to assess the predictive factors of inap therapies over a mid-term follow-up (FU) period after SICD implantation.
All pts implanted with an S-ICD and a FU above 6 months were included in a cross-sectional monocentric study. Data from preoperative screening with a thorough ECG study (amplitude of QRS complex, T wave and QRS:T ratio in leads I, II and III) has been collected. Pts were followed by remote monitoring.
One hundred and twenty-four pts (50±14 years old, male 84%) were included. Indications were: primary 73% and secondary prevention 27% (ischemic cardiopathy 39%; hypertrophic 8%; dilated 36%; channelopathy 2%). During a mean FU of 25±16 months, 29 pts (23%) experienced at least one therapy: 15 pts with appropriate (12%) and 15 pts with inap shocks (12%). A total of 22 inap shocks have been observed after a mean FU period of 15±18 months (1.5±1 inap shock per pt, several shocks for 4 pts). Causes were: supraventricular arrhythmias (33%), T wave (20%) and noise (53%) oversensing. The number of eligible vectors during preoperative screening was correlated with the occurrence of inap shocks (−0.23; P<0.05). ECG criteria measured in lead I were significantly correlated with inap therapies: QRS and T wave amplitude, respectively −0.23 and 0.3 (P<0.01), and the QRS:T ratio in lead I (−0.34; P<0.01). Of note, the untreated events related to T wave or noise oversensing during the FU were correlated with inap shocks (0.32; P<0.01) (Fig. 1).
Inap therapies remain frequent with S-ICD. Preoperative screening (number of eligible vectors) and ECG data may be taken into consideration to identify patients at high risk for inap shocks.
Le texte complet de cet article est disponible en PDF.
Publié par Elsevier Masson SAS.